GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

Reports Q2 revenue $5,000 vs $5,000 last year. “Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results. Since ALT lacks a marketed ...

Under these assumptions, Altimmune could have an estimated revenue of around $2.3B ($77B X 3 %). In my opinion, this could be a conservative estimate of the possible Pemvidutide sales in 6 years.

Altimmune has gone all-in on pemvidutide, a GLP-1/glucagon dual receptor agonist, and has the potential to secure blockbuster status, but they run the risk of regulatory failure.

Altimmune says pemvidutide given ‘clean safety bill of health’ by FDA TipRanks Nov. 11, 2024, 01:45 PM ...

--Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic ...

The firm, which argues that pemvidutide "appears differentiated among GLP-1 compounds," reiterates a Buy rating and $12 price target on Altimmune shares.Published first on TheFly – the ultimate ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Altimmune's phase 2 trial successfully demonstrated that pemvidutide can help achieve meaningful weight loss while simultaneously maintaining healthy muscle mass in most patients tested.

Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes ...